NINTIB 150 is a prescription medicine containing Nintedanib. It belongs to a class of drugs called tyrosine kinase inhibitor and works as an anti-fibrotic agent . it slows down lung tissue scarring and tumor cell multiplication. It does not reverse existing lung damage , but it help slow the loss of lung function in chronic fibrosing and idiopathic pulmonary fibrosis and systematic sclerosis –associated lung disease.
WHAT IS NINTIB 150 MG CAPSULES?
NINTIB 150 mg capsules contain NINTEDANIB, a prescription medicine belonging to a class of drugs called tyrosine kinase inhibitors. It is used as an anti-fibrotic and anti-neoplastic therapy to manage progressive lung or tumor conditions . they target multiple kinase pathways involved in scarring and blood vessel growth .
Key classification:
- Drug class: Tyrosine kinase inhibitor (TKI)
- Therapeutic class: Antifibrotic agent and anti-neoplastic agent
- ATC code: LO1EX09
- Role in persevering lung function: NINTIB 150 mg works as an tyrosine kinase inhibitor to slow the progression of lung scarring . By blocking specific cellular signals and growth factors that cause lung tissue to thicken and stiffen, it reduces the annual rate of decline in forced vital capacity (FCV) , helping preserve remaining respiratory capacity over time.
- Mechanism Of action: it targets enzyme signals responsible for inflammation and tissue remolding. It also lowers the deposit of extracellular matrix materials that create stiff scar tissue. It slows down unexplained ,progressive lung stiffening . it also controls lung involvement tied to systemic sclerosis . it also limits ongoing damage in chronic interstitial lung diseases.
WHAT ARE THE MEDICAL USES OF NINTIB 150 MG CAPSULES?
Medical uses of NINTIB 150 mg capsules are:
NINTIB 150 mg is a prescription medication ,sometimes manufactured by CIPLA, used to treat idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung disease and systematic sceloris-associated ILD. The medication designed to taken orally to help manage these conditions .
- Slows the progression of lung scaring
NINTAB 150 mg contains nintdanib, an anti-fibrotic medication that blocks tyrosine kinase enzymes. It slows the buildup of scar tissue and reduces the decline of lung function in conditions like idiopathic pulmonary fibrosis , but it does not cure or reverse existing lung damage.
- Helps preserve lung function
NINTIB 150 mg slows down lung tissue scarring and stiffness to help preserve remaining lung function in patients with chronic fibrosing lung diseases, though it does not cure. It reduces fibroblast activity to stop lung tissue from thickening and stiffening further. It also slows the overall rate of decline in respiratory capacity.
2)PROGRESSIVE PLUMONARY FIBROSIS (PPF)
NINTIB 150 mg is used to treat progressive fibrosing interstitial lung diseases, including iodiopathic pulmonary fibrosis (IPF) and systematic sceloris-associated ILD. It works by blocking cellular signals that cause lung scarring, helping to slow down the loss of lung function.
- Management of chronic fibrosing interstitial lung diseases
NINTIB 150 mg a targeted tyrosine kinase inhibitor. It manages chronic fibrosing interstitial lung diseases with a progressive phenotype, iodiopathic pulmonary fibrosis and systematic sceloris-associated ILD by blocking growth factors that cause lung scarring, thereby slowing disease progression.
- Reduces the decline in lung function
NINTIB 150 mg contains NINTEDANIB, that helps reduce the rate of decline in lung function. It is prescribed for adults with idiopathic pulmonary fibrosing interstitial lung diseases and systematic sclerosis-associated ILD . it is used to treat people with chronic interstitial lung diseases in which lung fibrosis continues to progress or becomes worse.
3)SYSTEMATIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASES (SSC-ILD)
NINTIB 150 mg capsule is a targeted tyrosine kinase inhibitor used to slow the annual rate of decline in forced vital capacity (FCV) in patients with systematic sclerosis –associated interstitial lung disease .
- Helps manage lung fibrosis associated with systematic sclerosis
NINTIB 150 mg contains NINTEDANIB, an oral tyrosine kinase inhibitor that slows lung function decline in patients with systematic scelorsis-associated interstitial lung disease (SSc-ILD) .it is taken twice daily with food to help reduce fibrous scar tissue formation in lungs.
- Supports long-term respiratory health
NINTIB 150 mg capsule contains Nintedanib, an antifibrotic medication that supports long-term progressive scarring and stiffening of lung tissue in conditions like idiopathic pulmonary fibrosis (IPF) and chronic fibrosing lung diseases (ILDS).
HOW NINTIB 150 MG CAPSULE WORK?
NINTIB 150 mg capsule contains nintedanib , which works as a it blocks specific enzyme triyosine kinase inhibitor it blocks the signals that cause lung tissues to scar or tumor cells to multiply. This action slows down the worsening of fibrotic lung diseases and helps control cancer cells growth.it works by the following ways:
- Mechanism of action of NINTEDANIB
NINTIB 150 contains nintedanib, which is a small –molecule tyrosine- kinase inhibitor (TKI), which works by competitively binding to intracellular ATP binding sites on specific growth factor receptors. This action blocks downstream signaling cascades that drive the division, migration and survival of the cells responsible for scarring and tumor growth.
- Inhibits multiple tyrosine kinase receptors involved in fibrosis
NINTIB 150 mg contains nintedanib a multi-targeted tyrosine kinase inhibitor that blocks key receptors like PDGFR, FGFR and VEGFR. By inhibiting these pathways.and proliferation , slowing lung tissue scarring in conditions like idiopathic pulmonary fibrosis.
- Reduces fibroblast activity and scar tissue formation
NINTIB 150 works by blocking specific cellular enzymes called tyrosine kinases. This action successfully reduces fibroblast proliferation, migration and activation ,which slows down the buildup of lung scar tissue in conditions like idiopathic pulmonary fibrosis (IPF).
- Slows disease progression
NINTIB 150 mg twice daily slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) and other progressive diseases (ILDS) by significantly reducing the annual rate of decline in forced vital capacity (FVC).
CONCLUSION
Clinical trial shows that NINETIB 150 mg significantly slows the progression of lung fibrosis . it achieves this by reducing the annual rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstinal lung diseases.
FREQUENTLY ASKED QUESTIONS (FAQs):
QUESTION: WHAT ARE NINTIB 150 MG CAPSULES USED FOR?
NINTINIB 150 mg capsule contains NINTDANIB , a kinase inhibitor used to slow down lung tissue scarring and stiffness in adults with chronic fibrosing lung diseases. It helps preserve lung function , though it is not a cure.
QUESTION: HOW DOES NINTEDANIB WORK?
NINTEDANIB Is a multi-targeted tyrosine kinase inhibitor that slows lung scarring by blocking specific growth factors, stopping fibroblast cell growth, and reducing blood vessel formation in damaged cells.
QUESTION: CAN NINTENIB 150 MG CURE PLUMONARY FIBROSIS?
There is no cure for pulmonary fibrosis and nilotinib is not an approved for proven cure for the condition . it is a tyrosine kinase inhibitor primarily used for chronic myeloid leukemia and has shown anti-fibrotic properties in preclinical animal studies. It is not established for treating human pulmonary fibrosis.
REFRENCES:
1)https://m.indiamart.com/proddetail/tasigna-150-mg-capsule-22562862997.html
2)https://www.goodrx.com/tasigna/what-is?srsltid=AfmBOooUDmd9fFWjYhf4LEw3SmdaDroOxyvtaulfdYVTwbrUcLvlYnBi
